Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4041 DDI, Safety, and Efficacy in Healthy Volunteers and Opioid Use Disorder
NCT06406400Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD4041 in opioid use disorder (OUD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed drug concentration at Day 22, Area under concentration-time curve from time 0 to infinity at Day 22 and 2 more. Started May 2024; status: terminated.
02
Drugs
AZD4041
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06406400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406400.